Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Mol Cancer Res. 2013 Oct 3;11(12):1585–1596. doi: 10.1158/1541-7786.MCR-13-0358

Figure 5. Increased ERK activation upregulates FGF2 expression in resistant cells.

Figure 5

(A–B) Parental and resistant cells were treated with the MEK inhibitor U0126 to block ERK activation and FGF2 expression was examined by western blotting (A) and ELISA (B). Complete abrogation of ERK activation was observed within 6hrs of inhibitor treatment and a significant decrease in FGF2 expression (* P=0.0003).